KDM5C safeguards the appropriate timing of early neurodevelopment [ATAC-seq]

We generated human induced pluripotent cells from intellectual disability patients carrying the c.2T>C mutation in KDM5C (Called “Mutant”). We generated a paired, isogenic human iPS cell line (called “Corrected”) using CRISPR/Cas9 and PiggyBac gene-editing technologies and conducted neuronal differentiation based on “Yichen Shi et al. Nat. Protoc. 7, 1836–1846 (2012)” to define differences in gene expression between the Mutant and Corrected and Mutant and Corrected treated with either a Wnt inhibitor (indicated as "+inh") or activator (indicated as "+W") during neuronal differentiation. Overall design: ATAC-seq samples from KDM5C-Mutant, Corrected, Mutant+Inhibitor and Corrected+Activator (+W) cells were collected over the time course of neuronal differentiation. The time points used were: day 8, 12, 16, and day 32.